PL2808393T3 - Komórki z brakiem fukozylacji - Google Patents

Komórki z brakiem fukozylacji

Info

Publication number
PL2808393T3
PL2808393T3 PL14179885T PL14179885T PL2808393T3 PL 2808393 T3 PL2808393 T3 PL 2808393T3 PL 14179885 T PL14179885 T PL 14179885T PL 14179885 T PL14179885 T PL 14179885T PL 2808393 T3 PL2808393 T3 PL 2808393T3
Authority
PL
Poland
Prior art keywords
fucosylation
deficient cells
deficient
cells
Prior art date
Application number
PL14179885T
Other languages
English (en)
Polish (pl)
Inventor
Gang Chen
Darya Burakov
James P. Fandl
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL2808393T3 publication Critical patent/PL2808393T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271GDP-L-fucose synthase (1.1.1.271)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/52Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL14179885T 2009-06-02 2010-06-01 Komórki z brakiem fukozylacji PL2808393T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18340009P 2009-06-02 2009-06-02
US34885810P 2010-05-27 2010-05-27
EP14179885.0A EP2808393B1 (en) 2009-06-02 2010-06-01 Fucosylation-deficient cells
PCT/US2010/036914 WO2010141478A1 (en) 2009-06-02 2010-06-01 Fucosylation-deficient cells
EP10721096.5A EP2438171B1 (en) 2009-06-02 2010-06-01 Fucosylation-deficient cells

Publications (1)

Publication Number Publication Date
PL2808393T3 true PL2808393T3 (pl) 2018-04-30

Family

ID=42338231

Family Applications (3)

Application Number Title Priority Date Filing Date
PL14179885T PL2808393T3 (pl) 2009-06-02 2010-06-01 Komórki z brakiem fukozylacji
PL10721096T PL2438171T3 (pl) 2009-06-02 2010-06-01 Komórki z niedoborem fukozylacji
PL17192430T PL3279326T3 (pl) 2009-06-02 2010-06-01 Komórki z deficytem fukozylacji

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL10721096T PL2438171T3 (pl) 2009-06-02 2010-06-01 Komórki z niedoborem fukozylacji
PL17192430T PL3279326T3 (pl) 2009-06-02 2010-06-01 Komórki z deficytem fukozylacji

Country Status (16)

Country Link
US (8) US8409838B2 (enExample)
EP (3) EP3279326B1 (enExample)
JP (4) JP5744856B2 (enExample)
KR (2) KR101641526B1 (enExample)
CN (1) CN102459603B (enExample)
AU (1) AU2010256753B2 (enExample)
BR (1) BRPI1010035A2 (enExample)
CA (1) CA2764370C (enExample)
DK (3) DK3279326T3 (enExample)
ES (2) ES2661074T3 (enExample)
HU (1) HUE038596T2 (enExample)
IL (1) IL216624A (enExample)
PL (3) PL2808393T3 (enExample)
SG (1) SG176251A1 (enExample)
TW (1) TWI513818B (enExample)
WO (1) WO2010141478A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
TWI513818B (zh) 2009-06-02 2015-12-21 Regeneron Pharma 岩藻糖基化(fucosylation)-缺乏之細胞
AU2012226398B9 (en) 2011-03-06 2017-04-13 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2722673B1 (en) 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
US20150093782A1 (en) * 2013-10-01 2015-04-02 The University Of Wyoming Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production of recombinant glycoproteins
AU2015229591B2 (en) 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
CN106604930B (zh) * 2014-05-30 2021-10-29 新英格兰生物实验室公司 去糖基化试剂和方法
CA2954534C (en) * 2014-07-07 2023-04-04 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use
CN105671109B (zh) * 2014-11-20 2019-08-23 中国人民解放军军事医学科学院生物工程研究所 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法(一)
EP3925970A1 (en) 2015-11-02 2021-12-22 F. Hoffmann-La Roche AG Methods of making fucosylated and afucosylated forms of a protein
AU2017206006B2 (en) * 2016-01-06 2019-08-29 Outlook Therapeutics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
WO2017136433A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
WO2017184831A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
KR102906454B1 (ko) * 2016-04-20 2026-01-02 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
EP3339444A1 (en) * 2016-12-20 2018-06-27 Mabxience Research, S.L. Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
JP2021519068A (ja) 2018-03-26 2021-08-10 アムジェン インコーポレイテッド 細胞培養において産生される抗体の総非フコシル化グリコフォーム
SG11202101099PA (en) * 2018-08-29 2021-03-30 United Biopharma Inc Afucosylated antibodies and manufacture thereof
CN113423731B (zh) 2018-10-29 2024-05-14 株式会社免疫生物研究所 抗hiv抗体及其制造方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
KR20230017815A (ko) 2020-05-26 2023-02-06 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
AU2021283349A1 (en) 2020-06-03 2023-02-02 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies
CN112843234B (zh) * 2021-01-20 2022-09-06 四川大学华西第二医院 一种调控生物机体内gdp-甘露糖的浓度的装置
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
JP2024527235A (ja) 2021-06-22 2024-07-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗EGFRvIII抗体薬物コンジュゲート及びその使用
IL310012A (en) 2021-07-14 2024-03-01 Regeneron Pharma Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
KR20240169150A (ko) 2022-03-02 2024-12-02 리제너론 파아마슈티컬스, 인크. 항체 생산을 위한 생물반응기

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006070A (en) 1909-05-11 1911-10-17 George Walter Durbrow Method of and means for extracting micro-organisms and solids from water.
PT1914244E (pt) * 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
JP2001145488A (ja) 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のgdp−4−ケト−6−デオキシ−d−マンノース−3,5−エピメラーゼ−4−レダクターゼ遺伝子
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
WO2002031140A1 (en) * 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020150968A1 (en) 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
JP4323167B2 (ja) 2001-01-16 2009-09-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分泌タンパク質を発現する細胞の単離
BR0213761A (pt) 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
KR100585140B1 (ko) 2004-04-26 2006-05-30 삼성전자주식회사 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
MX2007015107A (es) 2005-06-03 2008-02-15 Genentech Inc Metodo para producir anticuerpos con funcion mejorada.
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
CA2679732A1 (en) 2007-03-07 2008-09-18 Glycofi, Inc. Production of glycoproteins with modified fucosylation
US7771997B2 (en) 2007-06-04 2010-08-10 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
EP2311864A4 (en) 2008-08-13 2013-07-31 Kyowa Hakko Kirin Co Ltd RECOMBINANT PROTEIN-S COMPOSITION
TWI513818B (zh) 2009-06-02 2015-12-21 Regeneron Pharma 岩藻糖基化(fucosylation)-缺乏之細胞
AU2012226398B9 (en) 2011-03-06 2017-04-13 Merck Serono S.A. Low fucose cell lines and uses thereof

Also Published As

Publication number Publication date
US20200080124A1 (en) 2020-03-12
DK2808393T3 (en) 2018-03-12
US9206455B2 (en) 2015-12-08
JP2015051021A (ja) 2015-03-19
WO2010141478A1 (en) 2010-12-09
HK1198180A1 (en) 2015-03-13
US20100304436A1 (en) 2010-12-02
TW201107469A (en) 2011-03-01
KR101641526B1 (ko) 2016-07-21
US20190024129A1 (en) 2019-01-24
EP2808393A3 (en) 2015-03-11
US10006070B2 (en) 2018-06-26
JP2016104045A (ja) 2016-06-09
US20160090410A1 (en) 2016-03-31
JP2017006147A (ja) 2017-01-12
DK3279326T3 (da) 2020-12-21
EP2808393A2 (en) 2014-12-03
HK1249547A1 (en) 2018-11-02
EP3279326A1 (en) 2018-02-07
PL2438171T3 (pl) 2015-04-30
US12054751B2 (en) 2024-08-06
EP2438171A1 (en) 2012-04-11
KR20120029443A (ko) 2012-03-26
US20170211115A1 (en) 2017-07-27
EP2808393B1 (en) 2018-01-10
ES2527173T3 (es) 2015-01-21
US20130164786A1 (en) 2013-06-27
AU2010256753A1 (en) 2012-01-12
IL216624A0 (en) 2012-02-29
SG176251A1 (en) 2011-12-29
US11560550B2 (en) 2023-01-24
BRPI1010035A2 (pt) 2015-08-25
JP6211642B2 (ja) 2017-10-11
IL216624A (en) 2015-02-26
HUE038596T2 (hu) 2018-10-29
JP2012528594A (ja) 2012-11-15
KR20140039340A (ko) 2014-04-01
US20230295583A1 (en) 2023-09-21
KR101441437B1 (ko) 2014-09-25
US8409838B2 (en) 2013-04-02
AU2010256753B2 (en) 2013-11-28
DK2438171T3 (en) 2015-01-26
CN102459603A (zh) 2012-05-16
HK1163745A1 (en) 2012-09-14
EP2438171B1 (en) 2014-12-17
TWI513818B (zh) 2015-12-21
CA2764370A1 (en) 2010-12-09
EP3279326B1 (en) 2020-10-14
PL3279326T3 (pl) 2021-03-08
US9550823B2 (en) 2017-01-24
CA2764370C (en) 2018-08-21
CN102459603B (zh) 2013-11-06
US20210254022A1 (en) 2021-08-19
ES2661074T3 (es) 2018-03-27
JP5744856B2 (ja) 2015-07-08

Similar Documents

Publication Publication Date Title
IL216624A0 (en) Fucosylation-deficient cells
GB0908613D0 (en) T Cell Reseptors
EP2457078A4 (en) NANOFLUIDIC CELL
EP2416373A4 (en) SOLAR CELL
PT3121928T (pt) Elemento de pilha de zinco-ar
EP2356697A4 (en) SOLAR CELL
GB201017421D0 (en) Cell
EP2441107A4 (en) THIN BATTERY
GB0920775D0 (en) Cells
GB0913469D0 (en) Cell support
ZA201202939B (en) Whole cell biocatalyst
GB201204123D0 (en) Drainage cell
IL208602A0 (en) Mezuzah case
GB0917143D0 (en) Cell stack
ZA201107671B (en) Photovoltaic cell
GB0901675D0 (en) Cells
GB0908223D0 (en) Cells
HUE052153T2 (hu) Fukoziláció-deficiens sejtek
GB0920035D0 (en) Cell
TWI372482B (en) Battery
GB0905615D0 (en) Cell line
GB2471262B (en) Photovoltaic cell
TWI365574B (en) Cell connector
GB0810505D0 (en) M cell
GB201019304D0 (en) Cells